Literature DB >> 19376640

The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy.

Doriane Gouas1, Hong Shi, Pierre Hainaut.   

Abstract

Hepatocellular Carcinoma (HCC) in high-incidence areas (sub-Saharan Africa, South-Eastern Asia) often contains a somatic mutation at codon 249 in TP53 (R249S). This mutation is rare in low-incidence areas of Europe and the United States. There is evidence that R249S occurs as the result of mutagenesis by aflatoxin in a context of HBV chronic infection. Here, we summarize the mechanisms of R249S formation and the possible role of p.R249S protein in HCC pathogenesis. Next, we discuss the significance of R249S as a biomarker to study the natural history of HCC and as a target for therapeutic approaches aimed at restoring wild-type p53 activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19376640     DOI: 10.1016/j.canlet.2009.02.057

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  49 in total

1.  Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas.

Authors:  Jingjing Jiao; Weibo Niu; Ying Wang; Keith Baggerly; Yuanqing Ye; Xifeng Wu; Dewitt Davenport; Jose Luis Almeda; Monica M Betancourt-Garcia; R Armour Forse; Heather L Stevenson; Gordon P Watt; Joseph B McCormick; Susan P Fisher-Hoch; Laura Beretta
Journal:  Cancer Prev Res (Phila)       Date:  2017-10-31

2.  Association of Aflatoxin and Gallbladder Cancer.

Authors:  Jill Koshiol; Yu-Tang Gao; Michael Dean; Patricia Egner; Chirag Nepal; Kristine Jones; Bingsheng Wang; Asif Rashid; Wen Luo; Alison L Van Dyke; Catterina Ferreccio; Michael Malasky; Ming-Chang Shen; Bin Zhu; Jesper B Andersen; Allan Hildesheim; Ann W Hsing; John Groopman
Journal:  Gastroenterology       Date:  2017-04-17       Impact factor: 22.682

Review 3.  The inflammatory inception of gallbladder cancer.

Authors:  Jaime A Espinoza; Carolina Bizama; Patricia García; Catterina Ferreccio; Milind Javle; Juan F Miquel; Jill Koshiol; Juan C Roa
Journal:  Biochim Biophys Acta       Date:  2016-03-12

Review 4.  Hepatocellular carcinoma and the risk of occupational exposure.

Authors:  Venerando Rapisarda; Carla Loreto; Michele Malaguarnera; Annalisa Ardiri; Maria Proiti; Giuseppe Rigano; Evelise Frazzetto; Maria Irene Ruggeri; Giulia Malaguarnera; Nicoletta Bertino; Mariano Malaguarnera; Vito Emanuele Catania; Isidoro Di Carlo; Adriana Toro; Emanuele Bertino; Dario Mangano; Gaetano Bertino
Journal:  World J Hepatol       Date:  2016-05-08

5.  Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding.

Authors:  Peng Liao; Shelya X Zeng; Xiang Zhou; Tianjian Chen; Fen Zhou; Bo Cao; Ji Hoon Jung; Giannino Del Sal; Shiwen Luo; Hua Lu
Journal:  Mol Cell       Date:  2017-12-07       Impact factor: 17.970

6.  Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells.

Authors:  Huai Wang; Peng Liao; Shelya X Zeng; Hua Lu
Journal:  Cancer Biol Ther       Date:  2019-11-21       Impact factor: 4.742

Review 7.  The tumor suppressor p53: from structures to drug discovery.

Authors:  Andreas C Joerger; Alan R Fersht
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02-10       Impact factor: 10.005

8.  TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia.

Authors:  Doriane A Gouas; Stphanie Villar; Sandra Ortiz-Cuaran; Pénélope Legros; Gilles Ferro; Gregory D Kirk; Olufunmilayo A Lesi; Maimuna Mendy; Ebrima Bah; Marlin D Friesen; John Groopman; Isabelle Chemin; Pierre Hainaut
Journal:  Carcinogenesis       Date:  2012-06       Impact factor: 4.944

Review 9.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

Review 10.  Somatic TP53 Mutations in the Era of Genome Sequencing.

Authors:  Pierre Hainaut; Gerd P Pfeifer
Journal:  Cold Spring Harb Perspect Med       Date:  2016-11-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.